Tenofovir Alafenamide(TAF)에 의한 간 섬유증의 퇴행
Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF) in Treatment-Naive CHB Related Fibrosis/Cirrhosis: a 240 Weeks Open-label Multicenter Study
Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to treat patients with chronic hepatitis B virus (HBV) infection. Whereas, the long-term effect of TAF to liver fibrosis is still unknown. Here, we enrolled treatment naive CHB patients with biopsy-proven significant fibrosis (METAVIR fibrosis stage ≥ F2). To characterize longitudinal histological changes and assess liver fibrosis regression, the second and third liver biopsies are planned at weeks 96 and 240, respectively. During this study, all subjects will be assessed for laboratory tests, imaging examination at baseline, first 12-week and every 24-week during follow-up.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 4단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Jidong Jia
- 전화번호: 86-010-63139246
- 이메일: jia_jd@ccmu.edu.cn
연구 연락처 백업
- 이름: Jialing Zhou
- 전화번호: 86-010-63138665
- 이메일: zhoujialing11@126.com
연구 장소
-
-
-
Beijing, 중국, 100069
- 모병
- Beijing YouAn Hospital, Capital Medical University
-
연락하다:
- Huiguo Ding, Doctoral degree
- 전화번호: 86-13911683832
- 이메일: dinghuiguo@medmail.com.cn
-
수석 연구원:
- Huiguo Ding, Doctor
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, 중국, 100015
- 모병
- Beijing Ditan Hospital, Capital Medical University
-
연락하다:
- Wen Xie
- 이메일: xiewen6218@163.com
-
-
Jiangsu
-
Suzhou, Jiangsu, 중국, 215131
- 모병
- The Fifth People's Hospital of Suzhou
-
연락하다:
- Chuanwu Zhu, Doctoral degree
- 전화번호: 86-13606202525
- 이메일: zhuchw@126.com
-
-
Jiangxi
-
Nanchang, Jiangxi, 중국, 330006
- 모병
- The Ninth Hospital of Nanchang
-
연락하다:
- Yali Zong, Doctoral degree
- 전화번호: 86-13907004199
- 이메일: zylnc@163.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, 중국, 200040
- 모병
- Huashan Hospital Fudan University
-
연락하다:
- Jiming Zhang
- 전화번호: 86-13816317838
- 이메일: jmzhang@fudan.edu.cn
-
Shanghai, Shanghai Municipality, 중국, 200021
- 모병
- Shuguang Hospital
-
연락하다:
- Chenghai Liu
- 이메일: chenghailiu@hotmail.com
-
Shanghai, Shanghai Municipality, 중국, 201199
- 모병
- Ruijin Hospital
-
연락하다:
- Qing Xie
- 전화번호: 86-13651804273
- 이메일: xieqingrjh@163.com
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, 중국, 300170
- 모병
- Tianjin Third Central Hospital
-
연락하다:
- Tao Han
- 이메일: hantaomd@126.com
-
Tianjin, Tianjin Municipality, 중국, 300192
- 모병
- Tianjin Second People's Hospital
-
연락하다:
- Ping Li
- 전화번호: 86-13920265719
- 이메일: tjlplxg@163.com
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- 18-69 years old (inclusive);
- BMI (18-30 kg/m2);
- Chronic hepatitis B virus (HBV) infection, defined as positive serum hepatitis B s-antigen (HBsAg) for more than 6 months; or chronic hepatitis B proven by live biopsy;
- Not received nucleoside (acid) analogue and/or interferon therapy (treatment-naive);
- Liver biopsy performed within 6 months before treatment and had readable biopsy slides or agrees to have a biopsy performed prior to baseline;
- METAVIR fibrosis stage ≥ F2;
- For patients without cirrhosis (F2/3), HBV DNA levels >2000 IU/mL before treatment; For patients with cirrhosis (F4), HBV DNA >20 IU/mL before treatment;
- ALT≤10 ULN before treatment;
- Creatinine clearance ≥ 50 mL/min;
- Agreement not to undertake other HBV systemic antiviral or interferon (IFN) regimens during participation in this study;
- Willing and able to provide written informed consent.
Exclusion Criteria:
- Patients with Child-Turcotte-Pugh(CTP)score ≥ 7;
- Patients with decompensated cirrhosis: including ascites, hepatic encephalopathy, esophageal varices bleeding or other complications of decompensated cirrhosis or liver transplantation;
- Patients co-infection with hepatitis C virus (HCV), human immunodeficiency virus (HIV), or hepatitis delta virus (HDV), or alcoholic liver diseases, autoimmune liver disease, genetic liver disease, drug-induced liver injury, non-alcoholic fatty liver disease or other chronic liver diseases;
- Patients with evidence of hepatocellular carcinoma (HCC) by imaging with or without AFP;
- Patients with other uncured malignant tumors;
- Patients with organ or bone marrow transplantation;
- Patients currently receiving therapy with immunomodulators (eg, corticosteroids, etc.), investigational agents, nephrotoxic agents, or agents susceptible of modifying renal excretion;
- Patients who are allergic to any component of TAF;
- Patients who recently or newly started bisphosphate (within 1 month);
- Patients with active alcohol or drug abuse or history of alcohol or drug abuse (hinder compliance with treatment, or participation in the study or interpretation of results considered by the Investigator);
- Patients with significant renal, cardiovascular, pulmonary, or neurological disease
- Males and females of reproductive potential who are unwilling to use an effective method of contraception during the study;
- Pregnant women, women who are breast feeding or who believe they may wish to become pregnant during the course of the study;
- Not suitable for this study identified by researchers.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: TAF group
TAF [Vemlidy® 25mg QD] monotherapy |
Subjects will be treated for 240 weeks with TAF [Vemlidy® 25mg QD] monotherapy
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Proportion of patients with fibrosis regression
기간: Week 96 and 240
|
Fibrosis stage decrease at least 1 point by Ishak score or "Predominantly Regressive" by "Beijing classification" |
Week 96 and 240
|
|
HBV DNA undetectable rate
기간: Week 96
|
Serum HBV DNA <20 IU/mL |
Week 96
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of liver stiffness decrease >= 30%
기간: Week 48, week 96, week 144, week 192 and week 240
|
Proportion of patients with liver stiffness decrease >= 30% from baseline to week 240 |
Week 48, week 96, week 144, week 192 and week 240
|
|
HBV DNA undetectable rate
기간: Week 24, week 48, week 72, week 144, week 192 and week 240
|
HBV DNA undetectable rate at week 24, 48, 72, 144, 192 and 240 |
Week 24, week 48, week 72, week 144, week 192 and week 240
|
|
ALT normalization rate
기간: Week 48, week 96, week 144, week 192 and week 240
|
Proportion of patients with ALT <= 1.0xULN |
Week 48, week 96, week 144, week 192 and week 240
|
|
HBeAg and HBsAg loss and seroconversion rate
기간: Week 48, week 96, week 144 and week 240
|
Proportions of patients with HBsAg loss and seroconversion to anti-HBs, and proportions of patients with HBeAg loss and seroconversion to anti-HBe. |
Week 48, week 96, week 144 and week 240
|
|
Changes in renal function
기간: Week 48, week 96, week 144, week 192 and week 240
|
Changes of eGFR (estimated Glomerular Filtration rate) from baseline to week 48, 96, 144, 192 and 240. |
Week 48, week 96, week 144, week 192 and week 240
|
|
Changes of bone mineral density
기간: Week 48, week 96, week 144, week 192 and week 240
|
Percentage changes in spine BMD and hip BMD from baseline to week 48, 96, 144, 192 and 240 |
Week 48, week 96, week 144, week 192 and week 240
|
|
Incidence of liver-related endpoint events
기간: Week 96 and week 240
|
liver-related endpoint events: decompensation, HCC, liver transplantation, liver-related death |
Week 96 and week 240
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Jidong Jia, Beijing Friendship Hospital, Capital Medical Hospital
간행물 및 유용한 링크
일반 간행물
- Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013 Feb 9;381(9865):468-75. doi: 10.1016/S0140-6736(12)61425-1. Epub 2012 Dec 10.
- Buti M, Fung S, Gane E, Afdhal NH, Flisiak R, Gurel S, Flaherty JF, Martins EB, Yee LJ, Dinh P, Bornstein JD, Mani Subramanian G, Janssen HL, George J, Marcellin P. Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. Hepatol Int. 2015 Apr;9(2):243-50. doi: 10.1007/s12072-015-9614-4. Epub 2015 Mar 13.
- Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, Ahn SH, Izumi N, Chuang WL, Bae H, Sharma M, Janssen HLA, Pan CQ, Celen MK, Furusyo N, Shalimar D, Yoon KT, Trinh H, Flaherty JF, Gaggar A, Lau AH, Cathcart AL, Lin L, Bhardwaj N, Suri V, Mani Subramanian G, Gane EJ, Buti M, Chan HLY; GS-US-320-0110; GS-US-320-0108 Investigators. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018 Apr;68(4):672-681. doi: 10.1016/j.jhep.2017.11.039. Epub 2018 Jan 17.
- Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, Hui AJ, Janssen HL, Chowdhury A, Tsang TY, Mehta R, Gane E, Flaherty JF, Massetto B, Gaggar A, Kitrinos KM, Lin L, Subramanian GM, McHutchison JG, Lim YS, Acharya SK, Agarwal K; GS-US-320-0110 Investigators. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016 Nov;1(3):185-195. doi: 10.1016/S2468-1253(16)30024-3. Epub 2016 Sep 22.
- Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, Hui AJ, Lim YS, Mehta R, Janssen HL, Acharya SK, Flaherty JF, Massetto B, Cathcart AL, Kim K, Gaggar A, Subramanian GM, McHutchison JG, Pan CQ, Brunetto M, Izumi N, Marcellin P; GS-US-320-0108 Investigators. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016 Nov;1(3):196-206. doi: 10.1016/S2468-1253(16)30107-8. Epub 2016 Sep 22.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- IN-CN-320-5613
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
We will consider sharing it after the primary outcome is published.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .